Develops oral and injectable products for men's health conditions, focusing on hormone replacement therapies and treatments for hypogonadism.
Lipocine Inc. is a dynamic clinical-stage biopharmaceutical company dedicated to advancing pharmaceutical products aimed at treating neuroendocrine and metabolic disorders. Central to its innovation strategy is the development of oral delivery solutions for drugs with poor bioavailability. At the forefront of its pipeline is TLANDO, an oral testosterone replacement therapy designed to provide a convenient treatment option for patients.
Beyond TLANDO, Lipocine's robust pipeline includes LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trials for non-cirrhotic non-alcoholic steatohepatitis. Additionally, LPCN 1111, another oral prodrug of testosterone tridecanoate, has also completed Phase II trials for hypogonadal men. The company is advancing LPCN 1148, a novel prodrug of testosterone and testosterone laurate tailored for managing decompensated cirrhosis, alongside LPCN 1154, which targets Postpartum depression with an investigational new drug application for a Phase 2 study.
Headquartered in Salt Lake City, Utah, Lipocine Inc. operates on the cutting edge of biopharmaceutical research and development. With a comprehensive portfolio of innovative therapies addressing diverse medical needs, Lipocine continues to expand its footprint in the healthcare industry. Through strategic advancements and clinical partnerships, the company remains committed to pioneering transformative treatments that improve patient outcomes globally.